SOAPware Learning CenterClinical Quality Measures User Guide (for 2011) Additional Measures (Choose 3 Additional Measures)NQF 0068 (Additional) - Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

NQF 0068 (Additional) - Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

Measure:  NQF 0068 (Additional Measure)

Measure Title: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

Measure Description:  Percentage of patients 18 years of age and older who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year and who had documentation of use of aspirin or another antithrombotic during the measurement year.

*REQUIRED FOR MEANINGFUL USE (MU): Click here to view the Meaningful Use Criteria.

Quality Measure Documentation Workflow

In order for the Clinical Quality Measure report to generate, the following must be documented in the relevant patient's chart:

1.  The patient must be 18 years of age and older and have at least one face-to-face encounter with the provider during the reporting period.

2.  Documentation that the patient was discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous trasluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year. Or documentation that the patient was diagnosed with ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year.  Inserting the shortcut code "PQRIivd" in the encounter Plan field will allow the user to select from a group of specific SMARText codes that can be used to document for this measure.  The encounter Plan field should include one of the following codes to document this information: 0068b or 0068c (0068a will not increase the denominator).

3.  Documentation of the use of aspirin or another antithrombotic during the measurement year.  The user should document this by inserting one of the following medications into the Summary Medications field or the encounter Medication field: Plavix (d04258), Ticlid (d00514) or Aspirin (d00170).

Measurement Calculation Details

Numerator Calculation:

The numerator for this measurement is calculated based on the following:

1.  The number of patient in the denominator that have documentation of the use of aspirin or another antithrombotic during the measurement year by inserting one of the following medications into the Summary Medications field or the encounter Medications field:

Plavix (d04258), Ticlid (d00514), Aspirin (d00170)

Denominator Calculation:

The denominator for this measurement is calculated based on the following:

1.  The number of patient that were 18 years of age or older and have at least one face-to-face encounter with the provider during the reporting period.

2.  And have documentation that the patient was discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous trasluminal coronary angioplasty (PTCA) from January 1-November 1 of the year prior to the measurement year. Or documentation that the patient was diagnosed with ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year.  This can be documented by using the shortcut code "PQRIivd" in the encounter Plan field and inserting one of the following codes: 0068b or 0068c (0068a, 0073b, 0075a and 0075b will not increase the denominator).

 

 

Report Clinical Quality Measures to CMS/States

All of the items listed in the above steps need to be documented as structured data (as detailed above) in order to allow the user to capture the numerator, denominator and percentage for this quality measure.

For information on how to export the numerator, denominator and percentage for each Clinical Quality Measure, Click here.

For more information on reporting clinical quality measures, Click here.